Department of Surgery

Department of Surgery

Open to Enrollment Clinical Trails

 

 1.  A randomized, open-label, multi-center trial to determine safety and efficacy of eculizumad in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy.

Principal Investigator:   Joseph Buell, MD

2.A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective,

RandomizedStudy of the Efficacy and Safety of LCP‑Tacro^™ Tablets, Once Daily,
Compared to Prograf^® Capsules, Twice Daily, in Combination with Mycophenolate Mofetil for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients

Principal Investigator:  Mary Killackey, MD

 

Key Inclusion Criteria:

 

• 18 to 70 years of age undergoing kidney transplantation either primary orre-transplant.

• Recipient of a deceased donor or non-HLA identical living related donor kidney.

 

For more information contact Becky Bazile at (504) 988-8260 or email at

Rebecca.Bazile@HCAHealthcare.com. 

 

3.     A randomized, open label, parallel-group, multi-center trial to compare the efficacy and safety of TachoSil versus Surgicel  Original for the secondary treatment of local bleeding in adult and pediatric patients undergoing hepatic resection surgery.

Principal Investigator:  Douglas Slakey, MD

 

Key Inclusion Criteria:

• 18 years or older.
  
  
• Planned liver resection for any reason.
  
  
• Minor to moderate bleeding after conventional resection procedure.

 

For more information contact William Nganongo at (504) 988-8687 or email at William.Nganongo@HCAHealthcare.com.

 

 

4.     A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm theReversal of Hepatorenal Syndrome Type 1 with Lucassin® (Terlipressin).

Principal Investigator:  Nathan Shores, MD

Key Inclusion Criteria:

• History of Cirrhosis with ascites.
  
  
• Doubling of creatinine within the last 2 weeks.
  
  
• Creatinine above 2.25, 48 hours after fluid challenge.
  
  For more information contact Delainna Bartholomew at (504) 988-6902 or email at  Delainna. Bartholomew@HCAHealthcare.com.

 

5.     A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza

 

Principal Investigator:  A. Brent Alper, MD

Key Inclusion Criteria:

• Greater than 1 year of age.
  
  
• Liver, kidney or both transplant recipient.
  
  
• Rapid diagnostic test positive for influenza.
  
  
• Symptoms suggestive of influenza like illness including, but not limited to fever or cough.

 

For more information contact Becky Bazile at (504) 988-8260 or email at

Rebecca.Bazile@HCAHealthcare.com. 

 

 

6.     The Effect of Zortress (everolimus) on Glucose Metabolism and Post-Transplant Diabetes in Kidney Transplant Patients

 Principal Investigator:   Douglas Slakey, M.D.

Key Inclusion Criteria:

 

• Non-Diabetic 18 to 70 years of age
  
  
• Undergoing kidney transplantation either primary orre-transplant
  
  
• Recipient of a deceased donor or living donor kidney.
  
  

 For more information contact William Nganongo at (504) 988-8687 or email at William.Nganongo@HCAHealthcare.com.

 

Closed to Enrollment Trials

 

1.     Molecular Profiling Analysis of Indeterminate Thyroid Nodule Fine Needle Aspirates to Determine Patterns Predictive of Benign or Malignant Disease

Principal Investigator: Emad Kandil, MD

2.     Belatacept Conversion Trial in Renal Transplantation.

Principal Investigator: Rubin Zhang, MD

 

3.     Belatacept Evaluation of Nephroprotection and Efficacy as a First-line Immunosuppression Trial- Extended Criteria Donors (BENEFIT-EXT)

Principal Investigator: Rubin Zhang, MD

 

4. Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients

      Principal Investigator:  Mary Killackey, MD